Scientists have shown in mice that skin cells re-programmed into brain stem cells, transplanted into the central nervous system, help reduce inflammation and may be able to help repair damage caused by multiple sclerosis (MS).
Our mouse study suggests that using a patient’s reprogrammed cells could provide a route to personalised treatment of chronic inflammatory diseases, including progressive forms of MS
The study, led by researchers at the University of Cambridge, is a step towards developing personalised treatments based on a patient’s own skin cells for diseases of the central nervous system (CNS).
In MS, the body’s own immune system attacks and damages myelin, the protective sheath around nerve fibres, causing disruption to messages sent around the brain and spinal cord. Symptoms are unpredictable and include problems with mobility and balance, pain, and severe fatigue.
Key immune cells involved in causing this damage are macrophages (literally ‘big eaters’), which ordinarily serve to attack and rid the body of unwanted intruders. A particular type of macrophage known as microglia are found throughout the brain and spinal cord – in progressive forms of MS, they attack the CNS, causing chronic inflammation and damage to nerve cells.
Recent advances have raised expectations that diseases of the CNS may be improved by the use of stem cell therapies. Stem cells are the body’s ‘master cells’, which can develop into almost any type of cell within the body. Previous work from the Cambridge team has shown that transplanting neural stem cells (NSCs) – stem cells that are part-way to developing into nerve cells – reduces inflammation and can help the injured CNS heal.
However, even if such a therapy could be developed, it would be hindered by the fact that such NSCs are sourced from embryos and therefore cannot be obtained in large enough quantities. Also, there is a risk that the body will see them as an alien invader, triggering an immune response to destroy them.
A possible solution to this problem would be the use of so-called ‘induced neural stem cells (iNSCs)’ – these cells can be generated by taking an adult’s skin cells and ‘re-programming’ them back to become neural stem cells. As these iNSCs would be the patient’s own, they are less likely to trigger an immune response.
Now, in research published in the journal Cell Stem Cell, researchers at the University of Cambridge have shown that iNSCs may be a viable option to repairing some of the damage caused by MS.
Using mice that had been manipulated to develop MS, the researchers discovered that chronic MS leads to significantly increased levels of succinate, a small metabolite that sends signals to macrophages and microglia, tricking them into causing inflammation, but only in cerebrospinal fluid, not in the peripheral blood.
Transplanting NSCs and iNSCs directly into the cerebrospinal fluid reduces the amount of succinate, reprogramming the macrophages and microglia – in essence, turning ‘bad’ immune cells ‘good’. This leads to a decrease in inflammation and subsequent secondary damage to the brain and spinal cord.
“Our mouse study suggests that using a patient’s reprogrammed cells could provide a route to personalised treatment of chronic inflammatory diseases, including progressive forms of MS,” says Dr Stefano Pluchino, lead author of the study from the Department of Clinical Neurosciences at the University of Cambridge.
“This is particularly promising as these cells should be more readily obtainable than conventional neural stem cells and would not carry the risk of an adverse immune response.”
The research team was led by Dr Pluchino, together with Dr Christian Frezza from the MRC Cancer Unit at the University of Cambridge, and brought together researchers from several university departments.
Dr Luca Peruzzotti-Jametti, the first author of the study and a Wellcome Trust Research Training Fellow, says: “We made this discovery by bringing together researchers from diverse fields including regenerative medicine, cancer, mitochondrial biology, inflammation and stroke and cellular reprogramming. Without this multidisciplinary collaboration, many of these insights would not have been possible.”
The Latest on: Personalised stem cell treatment
via Google News
The Latest on: Personalised stem cell treatment
- Comprehensive review of targeted therapy for colorectal canceron March 19, 2020 at 4:06 pm
Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and chemotherapy have long been ...
- Targeting PI3Kβ alone and with combination therapy in PTEN-deficient tumorson March 18, 2020 at 7:51 pm
AZD8186 in combination with paclitaxel, eribulin had synergistic effects on growth inhibition in PTEN loss cells. AZD8186 significantly enhanced the antitumor efficacy ... as well as The Sheikh ...
- A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal canceron March 18, 2020 at 11:44 am
BanNVs sensitized immune checkpoint programmed death receptor 1 (PD-1) on T cells, therefore, a combination of banNVs with aPD-1 conspicuously induced the therapy response and led to complete ...
- Oncotarget Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapyon March 18, 2020 at 9:59 am
AZD8186 in combination with paclitaxel, eribulin had synergistic effects on growth inhibition in PTEN loss cells. AZD8186 significantly enhanced the antitumor efficacy ... the Department of Breast ...
- Women's wellness: Sexual health after cancer treatmenton March 18, 2020 at 9:31 am
"The cells are not able to lubricate like they should ... While some issues may be straightforward, each patient deserves a personalized approach. "We can point them in the appropriate direction in ...
- GIOSTAR Mexico Inaugurates Brand New Premium Facilities in Cancun Rivieraon March 17, 2020 at 6:00 pm
opened a new clinic in the Cancun Riviera. The grand opening took place on March 13th where the attendees gather to celebrate the inauguration of these premium facilities. The leader stem cell ...
- Scaling the Cell and Gene Therapy Supply Chain for Growthon March 16, 2020 at 1:30 pm
Because autologous cell therapies are personalized products created for each specific patient ... Few manufacturers have the systems in place to track the condition of the cells from the moment that ...
- Cellular rewiring in lethal prostate cancer: the architect of drug resistanceon March 16, 2020 at 8:22 am
Cellular rewiring can be exploited by prostate cancer cells to acquire drug resistance by implementing alternative ... In this context, clinical and biomarker studies are warranted to establish ...
- Orthopedic Regenerative Medicine Market Detailed Analysis, Growth Factors, Top Key Companies, Trends, Developments and Forecast by 2027on March 16, 2020 at 6:18 am
Moreover, Personalized Stem Cells, Inc. (“PSC”), a human adipose-derived stem cell company ... New small molecule drugs are launched by market players for the treatment of bone disorders. For instance ...
- Personalized blood biopsies may provide signal of cancer recurrenceon March 16, 2020 at 5:14 am
Personalized blood biopsies, which scan patient blood samples for genetic ... Existing diagnostics aren't yet sensitive enough to tell whether a patient's initial therapy eliminated the disease or ...
via Bing News